Sinopep - Public Comps and Valuation Multiples

Sinopep Overview

About Sinopep

Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.

Founded

2009

HQ

Employees

n/a

Website

sinopep.com.cn

Sectors

Small Molecules
Drug Development & Therapeutics
BioTech
DeepTech

Financials

LTM Revenue $279M

LTM EBITDA $133M

EV

$1.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sinopep Financials

As of November 2025, Sinopep reported last 12-month revenue of $279M and EBITDA of $133M.

In the same period, Sinopep generated $193M in LTM gross profit and $74.1M in net income.

See Sinopep valuation multiples based on analyst estimates

Sinopep P&L

In the most recent fiscal year, Sinopep reported revenue of $230M and EBITDA of $96.6M.

Sinopep expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sinopep valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$279M	XXX	$230M	XXX	XXX	XXX
Gross Profit	$193M	XXX	$155M	XXX	XXX	XXX
Gross Margin	69%	XXX	68%	XXX	XXX	XXX
EBITDA	$133M	XXX	$96.6M	XXX	XXX	XXX
EBITDA Margin	47%	XXX	42%	XXX	XXX	XXX
EBIT	$84.3M	XXX	$74.2M	XXX	XXX	XXX
EBIT Margin	30%	XXX	32%	XXX	XXX	XXX
Net Profit	$74.1M	XXX	$57.1M	XXX	XXX	XXX
Net Margin	27%	XXX	25%	XXX	XXX	XXX
Net Debt	XXX	XXX	$130M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sinopep including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $279M. EBITDA for the last twelve months was $133M. In the most recent fiscal year, Sinopep achieved $230M in revenue and $96.6M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$279M	Analyst estimates available to subscribers	$230M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$193M	Analyst estimates available to subscribers	$155M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	69.1% gross margin	Analyst estimates available to subscribers	67.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$133M	Analyst estimates available to subscribers	$96.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	47.4% EBITDA margin	Analyst estimates available to subscribers	42.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$84.3M	Analyst estimates available to subscribers	$74.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	30.2% EBIT margin	Analyst estimates available to subscribers	32.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$74.1M	Analyst estimates available to subscribers	$57.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	26.5% net profit margin	Analyst estimates available to subscribers	24.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$130M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sinopep

This financial data table provides comprehensive performance metrics for Sinopep, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sinopep generated $279M in revenue over the last twelve months.
The company achieved $133M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $193M.
Net income over the last twelve months reached $74.1M.

Fiscal Year Performance

In the most recent fiscal year, Sinopep reported $230M in total revenue.
Fiscal year EBITDA was $96.6M.
The company maintained a gross profit margin of 67.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 42.1%.
Net profit margin reached 24.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sinopep. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sinopep Stock Performance

Sinopep has current market cap of CNY 11.8B (or $1.7B), and EV of CNY 13.3B (or $1.9B).

Market Cap Evolution

Sinopep Stock Data

As of December 3, 2025, Sinopep's stock price is CNY 37 (or $5).

See Sinopep trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.9B	$1.7B	XXX	XXX	XXX	XXX	$0.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sinopep Valuation Multiples

Sinopep's trades at 8.2x EV/Revenue multiple, and 19.4x EV/EBITDA.

See valuation multiples for Sinopep and 15K+ public comps

Sinopep Financial Valuation Multiples

As of December 3, 2025, Sinopep has market cap of $1.7B and EV of $1.9B.

Equity research analysts estimate Sinopep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sinopep has a P/E ratio of 22.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV (current)	$1.9B	XXX	$1.9B	XXX	XXX	XXX
EV/Revenue	6.7x	XXX	8.2x	XXX	XXX	XXX
EV/EBITDA	14.2x	XXX	19.4x	XXX	XXX	XXX
EV/EBIT	22.3x	XXX	25.3x	XXX	XXX	XXX
EV/Gross Profit	9.7x	XXX	n/a	XXX	XXX	XXX
P/E	22.5x	XXX	29.1x	XXX	XXX	XXX
EV/FCF	-17.4x	XXX	-19.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sinopep Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sinopep Margins & Growth Rates

Sinopep's last 12 month revenue growth is 17%

Sinopep's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Sinopep's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sinopep's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sinopep and other 15K+ public comps

Sinopep Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	17%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	47%	XXX	42%	XXX	XXX	XXX
EBITDA Growth	24%	XXX	72%	XXX	XXX	XXX
Rule of 40	49%	XXX	60%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	91%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	35%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial